Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

thorium Th 227 anetumab corixetan

A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:227Th anetumab corixetan
thorium Th 227 monoclonal antibody BAY2287411
thorium-227-labeled anetumab
thorium-227-labeled antibody-chelator conjugate BAY2287411
Code name:BAY 2287411
BAY2287411
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search